NCT06655480 is a Phase 2 clinical trial of [ARNI + SGLTi + AMR] in HFpEF, sponsored by National Medical Research Center for Cardiology, Ministry of Health of Russian Federation.

What drugs are being tested in NCT06655480?

Interventions in NCT06655480: [ARNI + SGLTi + AMR], [SGLTi + previously taken RAAS blocker].

What condition does NCT06655480 study?

NCT06655480 studies HFpEF, LVDD, Myocardial Fibrosis.

Is NCT06655480 still recruiting?

NCT06655480 is currently not yet recruiting. Last updated 19 February 2025.

Last reviewed 2025-02-19 · How we verify

NCT06655480

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEF

Not yet recruiting Phase 2 Last updated 19 February 2025

What this trial tests

Phase 2 trial testing [ARNI + SGLTi + AMR] in HFpEF in 50 participants. Not yet recruiting.

Timeline

18 March 2025

Primary endpoint
1 September 2026

31 December 2026

Quick facts

Lead sponsor	National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	18 March 2025
Primary completion	1 September 2026
Estimated completion	31 December 2026

Drugs / interventions tested

[ARNI + SGLTi + AMR] — full drug profile →
[SGLTi + previously taken RAAS blocker] — full drug profile →

Conditions studied

HFpEF — all drugs for HFpEF →
LVDD — all drugs for LVDD →
Myocardial Fibrosis — all drugs for Myocardial Fibrosis →

Sponsor

National Medical Research Center for Cardiology, Ministry of Health of Russian Federation

Who can join

Adults 40 to 80, any sex, with HFpEF or LVDD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with advanced heart failure with preserved ejection fraction (HFpEF) will be randomly assigned in open-label multicenter study to receive triple combination therapy with \[angiotensin receptor/neprilysin inhibitor \[ARNI\] + sodium-glucose cotransporter 2 inhibitor \[SGLTi\] + mineralocorticoid receptor antagonist \[MRA\]) or with individualized medical therapy \[SGLTi + renin-angiotensin system inhibitor \[RASi\] \[angiotensin receptor blocker \[ARB\] or angiotensin-converting enzyme inhibitor \[ACE-I\]), and will be treated for 52 weeks

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Signaling Pathways and Therapeutic Approaches in Post-Myocardial Infarction Fibrosis.
Ba G, Chen M. · · 2025 · PMID 41239739 · DOI 10.12659/msm.949030
The Prognostic Role of the Left Atrium in Hypertensive Patients with HFpEF: Does Function Matter More than Structure?
Ovchinnikov A, Potekhina A, Filatova A, Svirida O, et al · · 2025 · PMID 41010425 · DOI 10.3390/life15091483

Verify or expand the search:

Other recruiting trials for HFpEF

Currently open trials in the same condition.

NCT07270536 — Accelerated Pacing and Cardiac Filling Pressures During Exercise in Patients With Heart Failure With Preserved Ejection · NA · recruiting
NCT07147114 — Clinical Trial to Evaluate the Efficacy and Safety in Concomitant Administration of Macitentan and Dapagliflozin in Pati · Phase 4 · recruiting
NCT06916611 — Heart Failure With Preserved Ejection Fraction and Its Cardiac MR Characteristics of Different Subtypes · active not recruiting
NCT05115890 — Muscle Blood Flow Regulation in HFpEF · NA · recruiting
NCT06844032 — Predictors of Poor Prognosis in HFpEF · recruiting

Other National Medical Research Center for Cardiology, Ministry of Health of Russian Federation trials

Trials by the same sponsor.

NCT06683001 — National Heart Failure Registry · recruiting
NCT07452991 — ULTRAsound-assisted Catheter-guided Thrombolysis for Intermediate-high Risk Patients With PE · NA · recruiting
NCT06540352 — A Study to Select the Dose and Evaluate the Effectiveness and Safety of the Drug Refralon®, Tablets, 1 mg for Long-term · Phase 2 · active not recruiting
NCT06683040 — Evaluation of the Efficacy and Safety of Oxacom® in Patients With Pulmonary Arterial Hypertension · Phase 2, PHASE3 · active not recruiting
NCT06376630 — Study of Microvascular Dysfunction, CFR and Cardioprotective Effect of Early Administration of Esmolol in MI · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06655480 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Last refreshed: 19 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06655480.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing